The world’s Largest Sharp Brain Virtual Experts Marketplace Just a click Away
Levels Tought:
Elementary,Middle School,High School,College,University,PHD
| Teaching Since: | Apr 2017 |
| Last Sign in: | 338 Weeks Ago, 4 Days Ago |
| Questions Answered: | 12843 |
| Tutorials Posted: | 12834 |
MBA, Ph.D in Management
Harvard university
Feb-1997 - Aug-2003
Professor
Strayer University
Jan-2007 - Present
CASE STUDY
3-5 pages
Ending HIV: Sangamo Biosciences and Gene Editing 1. What were the pros and cons of Sangamo pursuing its gene editing programs alone
versus working with a partner?
2. Does the HIV program offer any special opportunities or challenges?
3. What do you think Sangamo should do regarding the HIV program? (Should it license
the technology to a large pharmaceutical? Should it form a joint venture with another
biotech or pharma company? If so, who?) (The answer to this question should be a full
page.)
-----------